MedPath

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Matching Placebo
Registration Number
NCT02127476
Lead Sponsor
Kyowa Kirin Co., Ltd.
Brief Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose and as multiple doses in patients with Prodromal Alzheimer's Disease (AD) or Mild to Moderate AD.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
57
Inclusion Criteria
  • Patients with prodromal AD or mild to moderate AD
  • Clinical Dementia Rating (CDR) score of 0.5, 1.0, or 2.0
  • Have a cognitive impairment
  • Low Aβ and high Tau in Cerebrospinal fluid (CSF)
  • Mini Mental State Examination (MMSE) score > 16 at Screening
Exclusion Criteria
  • Previous active treatment with an AD immunotherapy in an investigational study
  • Use of another investigational drug within 30 days of screening
  • History or presence of clinically significant seizures, brain trauma, transient ischemic attack, and/or cerebrovascular disease
  • Presence of a neurological condition that could be contributing to cognitive impairment above and beyond that caused by the subject's AD
  • Evidence of infection, tumor, or other clinically significant lesions that could indicate a dementia diagnosis other than AD

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
KHK6640KHK6640KHK6640
PlaceboMatching PlaceboPlacebo
Primary Outcome Measures
NameTimeMethod
Number of Participants with Adverse Events as a Measure of Safety and TolerabilityUp to 7 months

Safety assessment variables will include all adverse events (AEs) including serious and non-serious AEs, laboratory parameters (hematology, chemistry, and urinalysis), vital signs, 12-lead electrocardiograms, physical and neurological examinations, and brain MRI

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (9)

Department of Neurology and Alzheimer Center, VU University Medical Center

🇳🇱

Amsterdam, Netherlands

University Medical Centre Groningen (UMCG), Alzheimer Research Centre

🇳🇱

Groningen, Netherlands

UZ Gent, De Pintelaan 185

🇧🇪

Gent, Belgium

Military Medical Academy, Crnotravska 17,

🇷🇸

Belgrade, Serbia

Clinical Research Services Turku (CRST), Itäinen Pitkäkatu 4B,

🇫🇮

Turku, Finland

Memory Clinic, Malmo Minneskliniken, Memory Research Unit, Hs 33,

🇸🇪

Malmö, Sweden

Clinical Centre of Serbia, Neurology Clinic, Dr Subotica Starijeg 6 ,

🇷🇸

Belgrade, Serbia

Karolinska Stockholm Karolinska University Hospital, Huddinge, Dept. of Geriatrics/Memory Disorders Unit

🇸🇪

Stockholm, Sweden

Sahlgrenska Gothenburg, Minnesmottagningen, Wallinsgatan 6

🇸🇪

Mölndal, Sweden

© Copyright 2025. All Rights Reserved by MedPath